Luminex Corporation (NASDAQ:LMNX) announced its earnings results on Monday. The medical instruments supplier reported $0.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.06, Bloomberg Earnings reports. Luminex Corporation had a net margin of 9.52% and a return on equity of 6.11%. The business had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $74.38 million. During the same quarter in the prior year, the company posted $0.21 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis.
Luminex Corporation (NASDAQ:LMNX) traded up 0.14% during mid-day trading on Wednesday, reaching $21.38. 31,726 shares of the company’s stock traded hands. The stock has a market cap of $942.24 million, a P/E ratio of 66.19 and a beta of 0.29. The company has a 50 day moving average price of $20.27 and a 200-day moving average price of $20.17. Luminex Corporation has a 12 month low of $17.68 and a 12 month high of $22.27.
The company also recently declared a quarterly dividend, which was paid on Friday, October 13th. Shareholders of record on Friday, September 22nd were given a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 1.12%. The ex-dividend date of this dividend was Thursday, September 21st. Luminex Corporation’s dividend payout ratio (DPR) is currently 36.36%.
Several research analysts recently commented on the stock. BidaskClub cut shares of Luminex Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Monday, July 17th. ValuEngine upgraded shares of Luminex Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Jefferies Group LLC restated a “hold” rating and set a $21.00 target price on shares of Luminex Corporation in a report on Friday, October 20th. Finally, TheStreet lowered shares of Luminex Corporation from a “b” rating to a “c+” rating in a research report on Monday, August 7th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $20.00.
WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/11/01/luminex-corporation-lmnx-issues-quarterly-earnings-results-beats-estimates-by-0-06-eps.html.
In other Luminex Corporation news, Director Robert J. Cresci sold 19,631 shares of Luminex Corporation stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $18.98, for a total transaction of $372,596.38. Following the transaction, the director now directly owns 260,358 shares of the company’s stock, valued at approximately $4,941,594.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.90% of the stock is owned by insiders.
Luminex Corporation Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
What are top analysts saying about Luminex Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Luminex Corporation and related companies.